During the last session, CRISPR Therapeutics AG (NASDAQ:CRSP)’s traded shares were 1.19 million, with the beta value of the company hitting 1.77. At the end of the trading day, the stock’s price was $43.84, reflecting an intraday gain of 0.90% or $0.39. The 52-week high for the CRSP share is $83.50, that puts it down -90.47 from that peak though still a striking 16.7% gain since the share price plummeted to a 52-week low of $36.52. The company’s market capitalization is $3.76B, and the average trade volume was 2.18 million shares over the past three months.
CRISPR Therapeutics AG (CRSP) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.97. CRSP has a Sell rating from 0 analyst(s) out of 8 analysts who have looked at this stock. 2 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 6 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -1.28.
CRISPR Therapeutics AG (NASDAQ:CRSP) trade information
CRISPR Therapeutics AG (CRSP) registered a 0.90% upside in the last session and has traded in the red over the past 5 sessions. The stock spiked 0.90% in intraday trading to $43.84, hitting a weekly high. The stock’s 5-day price performance is -1.26%, and it has moved by 9.60% in 30 days. Based on these gigs, the overall price performance for the year is -47.65%.
The consensus price target of analysts on Wall Street is $67, which implies an increase of 34.57% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $65 and $95 respectively. As a result, CRSP is trading at a discount of -116.7% off the target high and -48.27% off the low.
CRISPR Therapeutics AG (CRSP) estimates and forecasts
In the rating firms’ projections, revenue will increase 54.70% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 6.36M as predicted by 15 analyst(s). Meanwhile, a consensus of 15 analyst(s) estimates revenue growth to 9.15M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 504k and 517k respectively. In this case, analysts expect current quarter sales to grow by 1,162.84% and then jump by 1,669.32% in the coming quarter.
While earnings are projected to return -10.94% in 2025, the next five years will return 15.84% per annum.
CRSP Dividends
CRISPR Therapeutics AG is due to release its next quarterly earnings in April. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
The next largest institutional holding, with 7.78 million shares, is of ARK INVESTMENT MANAGEMENT LLC’s that is approximately 9.1597% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $420.12 million.
Also, the Mutual Funds coming in first place with the largest holdings of CRISPR Therapeutics AG (CRSP) shares are ARK ETF Tr-ARK Innovation ETF and New Perspective Fund Inc . Data provided on Dec 31, 2024 indicates that ARK ETF Tr-ARK Innovation ETF owns about 6.44 shares. This amounts to just over 7.50 percent of the company’s overall shares, with a $282.2 million market value. The same data shows that the other fund manager holds slightly less at 4.69, or about 5.47% of the stock, which is worth about $205.64 million.
